Impact of ERCC2 gene polymorphism on HIV-1 disease progression to AIDS among North Indian HIV patients

被引：2

作者：

Sobti, Ranbir Chander ^{[1
]}

Berhane, Nega ^{[1
]}

Mahdi, Salih Abdul ^{[1
]}

Kler, Rupinder ^{[1
]}

Hosseini, Seyed Ali ^{[1
]}

Kuttiat, Vijish ^{[2
]}

Wanchu, Ajay ^{[2
]}

机构：

[1] Panjab Univ, Dept Biotechnol, Chandigarh 160014, India

[2] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India

来源：

MOLECULAR BIOLOGY REPORTS | 2011年 / 38卷 / 05期

关键词：

ERCC2; polymorphism; Disease progression; HIV; 1; CHEMOKINE RECEPTOR GENE; DNA-REPAIR GENES; XPD POLYMORPHISMS; BREAST-CANCER; EXCISION-REPAIR; VIRAL PHENOTYPE; INFECTION; RISK; CCR5; INDIVIDUALS;

D O I：

10.1007/s11033-010-9958-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

HIV/AIDS remains to be one of the killing diseases of mankind. Host genetic response is one of the factor which determine susceptibility to HIV and disease progression to AIDS. The aim of the present study was to evaluate the impact of ERCC2 Lyc (751) Gln (excision repair cross complementing rodent repair deficiency, complementation group 2) polymorphism on HIV-1 susceptibility and disease progression to AIDS, as this gene has been reported to intervene in degrading retroviral cDNA before it integrates with the host DNA. This case control study included 300 HIV seropositive cases and an equal number of HIV seronegative controls. DNA was isolated from the blood samples of study subjects and genotyping of ERCC2 was conducted by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) method. The Gln/Gln genotype showed a significant variation between cases and controls (P = 0.047, OR 1.71, 95% CI 1.00-2.93), indicating a possible role of susceptibility in reference to controls and disease progression when compared within cases.

引用

页码：2945 / 2952

页数：8

共 44 条

[1]

ANJA J, 2000, GENOMICS HUM GENET, V1, P409

[2] Polymorphism in the ERCC2 codon 751 is associated with arsenic-induced premalignant hyperkeratosis and significant chromosome aberrations [J].

Banerjee, Mayukh ;

Sarkar, Jyotirmoy ;

Das, Jayanta K. ;

Mukherjee, Angshuman ;

Sarkar, Ajoy K. ;

Mondal, Lakshmikanta ;

Giri, Ashok K. .

CARCINOGENESIS, 2007, 28 (03) :672-676

[3] ERCC2/XPD gene polymorphisms and cancer risk [J].

Benhamou, S ;

Sarasin, A .

MUTAGENESIS, 2002, 17 (06) :463-469

[4] Correlates of delayed disease progression in HIV-1-infected Kenyan children [J].

Chakraborty, R ;

Morel, AS ;

Sutton, JK ;

Appay, V ;

Ripley, RM ;

Dong, T ;

Rostron, T ;

Ogola, S ;

Palakudy, T ;

Musoke, R ;

D'Agostino, A ;

Ritter, M ;

Rowland-Jones, SL .

JOURNAL OF IMMUNOLOGY, 2005, 174 (12) :8191-8199

[5] Analysis of variants in DNA damage signalling genes in bladder cancer [J].

Choudhury, Ananya ;

Elliott, Faye ;

Iles, Mark M. ;

Churchman, Michael ;

Bristow, Robert G. ;

Bishop, D. Timothy ;

Kiltie, Anne E. .

BMC MEDICAL GENETICS, 2008, 9

[6]

David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911

[7] Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].

Dean, M ;

Carrington, M ;

Winkler, C ;

Huttley, GA ;

Smith, MW ;

Allikmets, R ;

Goedert, JJ ;

Buchbinder, SP ;

Vittinghoff, E ;

Gomperts, E ;

Donfield, S ;

Vlahov, D ;

Kaslow, R ;

Saah, A ;

Rinaldo, C ;

Detels, R ;

OBrien, SJ .

SCIENCE, 1996, 273 (5283) :1856-1862

[8]

Evans DL, 1997, AM J PSYCHIAT, V154, P630, DOI 10.1176/ajp.154.5.630

[9] Dual effect of CCR5 Delta 32 gene deletion in HIV-1-infected patients [J].

Garred, P ;

EugenOlsen, J ;

Iversen, AKN ;

Benfield, TL ;

Svejgaard, A ;

Hofmann, B ;

Koppelhus, U ;

Pedersen, C ;

Sorensen, AM ;

Katzenstein, T ;

Gerstoft, J ;

Skinhoj, P ;

Nielsen, JO ;

Dickmeiss, E .

LANCET, 1997, 349 (9069) :1884-1884

[10] Toward an understanding of the correlates of protective immunity to HIV infection [J].

Haynes, BF ;

Pantaleo, G ;

Fauci, AS .

SCIENCE, 1996, 271 (5247) :324-328

← 1 2 3 4 5 →